{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:40:47Z","timestamp":1790386847694,"version":"4.1.0"},"reference-count":182,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/jcp.0b013e31815ac4e5","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T01:27:58Z","timestamp":1236216478000},"page":"639-661","source":"Crossref","is-referenced-by-count":135,"title":["Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders"],"prefix":"10.1097","volume":"27","author":[{"given":"Matthew","family":"Byerly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Suppes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh-Van","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management.","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia.","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4088\/JCP.v65n1205","article-title":"Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.","volume":"65","author":"Misra","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects.","volume":"9","author":"Halbreich","year":"2003","journal-title":"J Psychiatr Pract"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.3.10.1381","article-title":"Antipsychotics: impact on prolactin levels.","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin inhibitor.","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.physiol.64.081501.131049","article-title":"Prolactin: the new biology of an old hormone.","volume":"64","author":"Goffin","year":"2002","journal-title":"Annu Rev Physiol"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocr Rev"},{"key":"R9-13-20210128","first-page":"71","article-title":"Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting.","volume":"76","author":"Fujimoto","year":"1990","journal-title":"Obstet Gynecol"},{"key":"R10-13-20210128","first-page":"959","article-title":"Pediatric reference ranges for prolactin.","volume":"38","author":"Cook","year":"1992","journal-title":"Clin Chem"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/000456328602300603","article-title":"Assays for prolactin: guidelines for the provision of a clinical biochemistry service.","volume":"23","author":"Jeffcoate","year":"1986","journal-title":"Ann Clin Biochem"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004850-199300830-00007","article-title":"A study on serum prolactin levels in schizophrenia: correlation between positive and negative symptoms.","volume":"8","author":"Kuruvilla","year":"1993","journal-title":"Int Clin Psychopharmacol"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.182.3.199","article-title":"Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences.","volume":"182","author":"Wieck","year":"2003","journal-title":"Br J Psychiatry"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archpsyc.1989.01810090055009","article-title":"The 24-hour profile of plasma prolactin in men with major endogenous depressive illness.","volume":"46","author":"Linkowski","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-3223(94)91147-9","article-title":"Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia.","volume":"35","author":"Rao","year":"1994","journal-title":"Biol Psychiatry"},{"issue":"suppl 4","key":"R16-13-20210128","first-page":"56","article-title":"Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.","volume":"63","author":"Maguire","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R17-13-20210128","first-page":"447","article-title":"Neither gynaecomastia nor galactorrhea is a common side effect of neuroleptics in male patients.","volume":"21","author":"Kaneda","year":"2000","journal-title":"Neuroendocrinol Lett"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-0447.1995.tb09758.x","article-title":"Galactorrhea: subjective response by schizophrenic patients.","volume":"91","author":"Wesselman","year":"1995","journal-title":"Acta Psychiatr Scand"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000119265","article-title":"Schulze, et al. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology.","volume":"33","author":"Windgassen","year":"1996","journal-title":"Neuropsychobiology"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0015-0282(16)60365-5","article-title":"Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia.","volume":"50","author":"Ataya","year":"1988","journal-title":"Fertil Steril"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1176\/ajp.156.4.631","article-title":"Sexual disturbances during clozapine and haloperidol treatment for schizophrenia.","volume":"156","author":"Hummer","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2710.2002.00378.x","article-title":"Gynaecomastia with sulpiride.","volume":"27","author":"Kaneda","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/026988110101500408","article-title":"Antipsychotic-induced hyperprolactinemia: a series of illustrative case reports.","volume":"15","author":"Haddad","year":"2001","journal-title":"J Psychopharmacol"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0920-9964(00)00061-X","article-title":"Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone.","volume":"48","author":"Mullen","year":"2001","journal-title":"Schizophr Res"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/713847170","article-title":"Frequency of sexual dysfunction and other reproductive side effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.","volume":"29","author":"Bobes","year":"2003","journal-title":"J Sex Marital Ther"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2125.2001.01352.x","article-title":"Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses.","volume":"51","author":"Melkersson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","article-title":"The effects of antipsychotic-induced hyperprolactinemia on the hypothalamic-pituitary-gonadal axis.","volume":"22","author":"Smith","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R30-13-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","article-title":"Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.","volume":"66","author":"Melkersson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0306-4530(02)00130-0","article-title":"What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?","volume":"28","author":"Knegtering","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","article-title":"Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.","volume":"31","author":"Kinon","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"R33-13-20210128","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00005053-198208000-00004","article-title":"Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients.","volume":"170","author":"Ghadirian","year":"1982","journal-title":"J Nerv Ment Dis"},{"issue":"suppl 2","key":"R34-13-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoendocrinology"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.v66n0309","article-title":"Male sexual dysfunction and quality of life in schizophrenia.","volume":"66","author":"Olfson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0006-3223(94)91164-9","article-title":"A pilot study of a structured interview addressing sexual functioning in men with schizophrenia.","volume":"35","author":"Burke","year":"1994","journal-title":"Biol Psychiatry"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/bjp.181.1.49","article-title":"Sexual dysfunction in patients taking conventional antipsychotic medication.","volume":"181","author":"Smith","year":"2002","journal-title":"Br J Psychiatry"},{"key":"R38-13-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","article-title":"A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.","volume":"24","author":"Knegtering","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone.","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.v63n0506","article-title":"Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.","volume":"63","author":"Kim","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R41-13-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.ijir.3901260","article-title":"A new atypical antipsychotic: quetiapine-induced sexual dysfunctions.","volume":"17","author":"Atmaca","year":"2005","journal-title":"Int J Impot Res"},{"issue":"suppl 1","key":"R43-13-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0306-4530(02)00109-9","article-title":"The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects.","volume":"28","author":"Tandon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R44-13-20210128","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","article-title":"Predictors of noncompliance in patients with schizophrenia.","volume":"63","author":"Perkins","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R45-13-20210128","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/ajp.149.6.844a","article-title":"Patients' opinions concerning side effects of depot neuroleptics.","volume":"149","author":"Buis","year":"1992","journal-title":"Am J Psychiatry"},{"key":"R46-13-20210128","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1017\/S0033291700036539","article-title":"Subjective utility ratings of neuroleptics in treating schizophrenia.","volume":"20","author":"Finn","year":"1990","journal-title":"Psychol Med"},{"key":"R47-13-20210128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","article-title":"Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.","volume":"19","author":"Lambert","year":"2004","journal-title":"Eur Psychiatry"},{"key":"R48-13-20210128","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1592\/phco.26.6.748","article-title":"Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.","volume":"26","author":"Szarfman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"R51-13-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1191\/0960327106ht643oa","article-title":"Hyperprolactinemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer.","volume":"25","author":"Harvey","year":"2006","journal-title":"Hum Exp Toxicol"},{"key":"R52-13-20210128","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jnci\/91.7.629","article-title":"Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women.","volume":"91","author":"Hankinson","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R53-13-20210128","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer.","volume":"59","author":"Wang","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 2","key":"R54-13-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0306-4530(02)00129-4","article-title":"Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents.","volume":"28","author":"Naidoo","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R55-13-20210128","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM198711053171901","article-title":"Hip fractures and the use of estrogen in postmenopausal women: the Framingham Study.","volume":"317","author":"Kiel","year":"1987","journal-title":"N Engl J Med"},{"key":"R56-13-20210128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial.","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R57-13-20210128","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jama.291.14.1769","article-title":"The WHI estrogen-alone trial-do things look any better?","volume":"291","author":"Hulley","year":"2004","journal-title":"JAMA"},{"key":"R58-13-20210128","first-page":"692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea.","volume":"75","author":"Biller","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"R59-13-20210128","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-104-6-777","article-title":"Osteoporosis in men with hyperprolactinemic hypogonadism.","volume":"104","author":"Greenspan","year":"1986","journal-title":"Ann Intern Med"},{"key":"R60-13-20210128","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","article-title":"Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism.","volume":"110","author":"Greenspan","year":"1989","journal-title":"Ann Intern Med"},{"key":"R61-13-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral density in treated and untreated hyperprolactinemic amenorrhea.","volume":"64","author":"Schlechte","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"R62-13-20210128","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1210\/jcem-59-6-1050","article-title":"Vertebral bone mineral density content in hyperprolactinemic women.","volume":"59","author":"Koppelman","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"R63-13-20210128","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1176\/appi.ajp.160.9.1618","article-title":"Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study.","volume":"160","author":"Abraham","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R64-13-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v64n0704","article-title":"Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.","volume":"64","author":"Becker","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"suppl 3","key":"R65-13-20210128","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.1016\/S0924-977X(02)80462-X","article-title":"Bone mineral density in premenopausal women with antipsychotic-induced hyperprolactinemia.","volume":"12","author":"Akande","year":"2002","journal-title":"Eur Neuropsychopharmacol"},{"key":"R66-13-20210128","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00006842-199509000-00011","article-title":"Decreased bone mineral density in medicated psychiatric patients.","volume":"57","author":"Halbreich","year":"1995","journal-title":"Psychosom Med"},{"key":"R67-13-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":"Effects of long term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.","volume":"184","author":"Meaney","year":"2004","journal-title":"Br J Psychiatry"},{"key":"R68-13-20210128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.jcp.0000162798.87249.4d","article-title":"Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment.","volume":"25","author":"Howes","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R69-13-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","article-title":"Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?","volume":"25","author":"O'Keane","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R70-13-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/schbul\/22.3.447","article-title":"Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes.","volume":"22","author":"Halbreich","year":"1996","journal-title":"Schizophr Bull"},{"key":"R71-13-20210128","first-page":"198","article-title":"Osteoporosis associated with neuroleptic treatment. A case report.","volume":"35","author":"Kartaginer","year":"1990","journal-title":"J Reprod Med"},{"key":"R72-13-20210128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0165-1781(83)90002-1","article-title":"Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis.","volume":"9","author":"Meltzer","year":"1983","journal-title":"Psychiatry Res"},{"key":"R73-13-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0306-4530(90)90033-6","article-title":"Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.","volume":"15","author":"Copolov","year":"1990","journal-title":"Psychoneuroendocrinology"},{"key":"R74-13-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00023210-199810030-00005","article-title":"Hyperprolactinemia in antipsychotic-treated patients: guidelines for avoidance and management.","volume":"10","author":"Hamner","year":"1998","journal-title":"CNS Drugs"},{"key":"R75-13-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1681.1992.tb00511.x","article-title":"A study of serum prolactin levels in schizophrenia: comparison of males and females.","volume":"19","author":"Kuruvilla","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R76-13-20210128","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/archpsyc.1978.01770340072008","article-title":"Relation of plasma prolactin to clinical response in schizophrenic patients.","volume":"35","author":"Gruen","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"R77-13-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","article-title":"The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.","volume":"26","author":"Crawford","year":"1997","journal-title":"Schizophr Res"},{"key":"R78-13-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \"Seroquel\" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.","volume":"42","author":"Aravanitis","year":"1997","journal-title":"Biol Psychiatry"},{"key":"R79-13-20210128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.","volume":"18","author":"Goff","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R80-13-20210128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0165-1781(83)90001-X","article-title":"Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response.","volume":"9","author":"Meltzer","year":"1983","journal-title":"Psychiatry Res"},{"key":"R81-13-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00427590","article-title":"High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.","volume":"67","author":"Bjorndal","year":"1980","journal-title":"Psychopharmacology"},{"key":"R82-13-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00381354","article-title":"Haloperidol plasma levels and clinical response in paranoid schizophrenics.","volume":"234","author":"Linkowski","year":"1984","journal-title":"Eur Arch Psychiatr Neurol Sci"},{"key":"R83-13-20210128","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/0024-3205(81)90514-2","article-title":"Radioimmunoassay of haloperidol in human serum: correlation of serum haloperidol with serum prolactin.","volume":"29","author":"Poland","year":"1981","journal-title":"Life Sci"},{"key":"R84-13-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-1781(84)90108-2","article-title":"Prolactin response to single and multiple doses of haloperidol in schizophrenic patients.","volume":"1","author":"Ravichandran","year":"1984","journal-title":"Psychiatry Res"},{"key":"R85-13-20210128","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archpsyc.1980.01780220107012","article-title":"Serum haloperidol determinations in psychiatric patients: comparison of methods and correlation with serum prolactin level.","volume":"37","author":"Rubin","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"R86-13-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0306-4530(80)90015-3","article-title":"The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations.","volume":"5","author":"Rubin","year":"1980","journal-title":"Psychoneuroendocrinology"},{"key":"R87-13-20210128","first-page":"357","article-title":"Serum prolactin as a correlate of clinical response to haloperidol.","volume":"11","author":"Van Putten","year":"1991","journal-title":"J Clin Psychopharmacol"},{"key":"R88-13-20210128","first-page":"59","article-title":"Long-term effects of neuroleptic drugs on the neuroendocrine system.","volume":"40","author":"Meltzer","year":"1985","journal-title":"Adv Biochem Psychopharmacol"},{"key":"R89-13-20210128","first-page":"59","article-title":"Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance?","volume":"3","author":"Naber","year":"1979","journal-title":"Commun Psychopharmacol"},{"key":"R90-13-20210128","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/0006-3223(86)90124-1","article-title":"Possible associations among plasma prolactin levels, tardive dyskinesia and paranoia in treated male schizophrenic patients.","volume":"21","author":"Csernansky","year":"1986","journal-title":"Biol Psychiatry"},{"key":"R91-13-20210128","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/0006-3223(95)00589-7","article-title":"High plasma prolactin levels after long-term neuroleptic treatment.","volume":"39","author":"Zelaschi","year":"1996","journal-title":"Biol Psychiatry"},{"key":"R92-13-20210128","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0447.1981.tb00794.x","article-title":"Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.","volume":"64","author":"Chouinard","year":"1981","journal-title":"Acta Psychiatr Scand"},{"key":"R93-13-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2265.1976.tb01953.x","article-title":"Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups.","volume":"5","author":"DeRivera","year":"1976","journal-title":"Clin Endocrinol"},{"key":"R96-13-20210128","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.","volume":"156","author":"Breier","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R97-13-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00406-004-0505-2","article-title":"Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.","volume":"254","author":"de Leon","year":"2004","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R98-13-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.","volume":"65","author":"Volavka","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R99-13-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","article-title":"Elevation of prolactin levels by atypical antipsychotics.","volume":"159","author":"Turrone","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R100-13-20210128","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4088\/JCP.v61n0907","article-title":"A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.","volume":"61","author":"Guille","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R101-13-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/104454602760219126","article-title":"Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.","volume":"12","author":"Alfaro","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R102-13-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R103-13-20210128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.","volume":"158","author":"Conley","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R104-13-20210128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pnpbp.2003.10.006","article-title":"Adverse effects of risperidone and haloperidol treatment in schizophrenia.","volume":"28","author":"Yen","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R105-13-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients.","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"R106-13-20210128","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.","volume":"166","author":"Peuskens","year":"1995","journal-title":"Br J Psychiatry"},{"key":"R107-13-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/00926230490465082","article-title":"An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction.","volume":"30","author":"Byerly","year":"2004","journal-title":"J Sex Marital Ther"},{"key":"R108-13-20210128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorder.","volume":"17","author":"Tran","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R109-13-20210128","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.","volume":"22","author":"David","year":"2000","journal-title":"Clin Ther"},{"key":"R110-13-20210128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00406-005-0622-6","article-title":"Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms.","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R111-13-20210128","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","article-title":"Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.","volume":"161","author":"Hirschfeld","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R112-13-20210128","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania. a double-blind, placebo-controlled comparison of efficacy and safety.","volume":"159","author":"Sachs","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R113-13-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","article-title":"Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial.","volume":"182","author":"Yatham","year":"2003","journal-title":"Br J Psychiatry"},{"key":"R114-13-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.187.3.229","article-title":"Risperidone in the treatment of acute mania.","volume":"187","author":"Khanna","year":"2005","journal-title":"Br J Psychiatry"},{"key":"R115-13-20210128","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1176\/ajp.161.10.1925","article-title":"Prolactin elevation with ziprasidone.","volume":"161","author":"Lusskin","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R116-13-20210128","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/cap.2005.15.885","article-title":"Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.","volume":"15","author":"Hellings","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R117-13-20210128","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1176\/appi.ajp.162.8.1542-a","article-title":"Reversal of symptomatic hyperprolactinemia by aripiprazole.","volume":"162","author":"Wahl","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R118-13-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.jcp.0000203194.58087.9a","article-title":"Risperidone-induced symptomatic hyperprolactinemia in adolescents.","volume":"26","author":"Holzer","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R119-13-20210128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/cap.2004.14.350","article-title":"A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents.","volume":"14","author":"Saito","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R121-13-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1525-8610(04)70344-8","article-title":"The effects of antipsychotic treatment on prolactin concentrations in elderly patients.","volume":"4","author":"Kinon","year":"2003","journal-title":"J Am Med Dir Assoc"},{"key":"R122-13-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"R123-13-20210128","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","article-title":"Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.","volume":"61","author":"Kinon","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R124-13-20210128","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4088\/JCP.v64n1008","article-title":"High-dose olanzapine and prolactin levels.","volume":"64","author":"Karagianis","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R125-13-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placeboand haloperidol: acute phase results of the North American double-blind olanzapine trial.","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"R126-13-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.","volume":"57","author":"Purdon","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R127-13-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cap.1999.9.239","article-title":"Elevated prolactin in pediatric patients on typical and atypical antipsychotics.","volume":"9","author":"Wudarsky","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R128-13-20210128","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. A double-blind, randomized, placebo-controlled trial.","volume":"57","author":"Street","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R129-13-20210128","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. The Olanzapine HGEH Study Group.","volume":"156","author":"Tohen","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R130-13-20210128","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group.","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R131-13-20210128","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1176\/appi.ajp.159.6.1011","article-title":"Olanzapine versus divalproex in the treatment of acute mania.","volume":"159","author":"Tohen","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R132-13-20210128","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.schres.2003.06.001","article-title":"Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia.","volume":"66","author":"Buckley","year":"2004","journal-title":"Schizophr Res"},{"key":"R133-13-20210128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.","volume":"54","author":"Small","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"R134-13-20210128","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.v65n0516","article-title":"A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.","volume":"65","author":"Emsley","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R135-13-20210128","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1185\/030079904125004510","article-title":"Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.","volume":"20","author":"Buckley","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R136-13-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S0033291799001476","article-title":"A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia.","volume":"30","author":"Copolov","year":"2000","journal-title":"Psychol Med"},{"key":"R137-13-20210128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002130050603","article-title":"A comparison of bid and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia.","volume":"137","author":"King","year":"1998","journal-title":"Psychopharmacology"},{"issue":"suppl 1","key":"R138-13-20210128","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1046\/j.1365-2125.2000.00147.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.","volume":"49","author":"Miceli","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R139-13-20210128","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4088\/JCP.v65n0918f","article-title":"Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report.","volume":"65","author":"Anghelescu","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R140-13-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.yic.0000182114.65134.81","article-title":"Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.","volume":"21","author":"Kane","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R141-13-20210128","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v65n1207","article-title":"Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.","volume":"65","author":"Addington","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R142-13-20210128","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","article-title":"Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.","volume":"23","author":"Weiden","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R143-13-20210128","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4088\/JCP.v64n0514","article-title":"Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.","volume":"64","author":"Weiden","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R144-13-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80, and 169 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.","volume":"17","author":"Arato","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"R145-13-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res"},{"key":"R146-13-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R148-13-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"R149-13-20210128","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R150-13-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/08830738050200071301","article-title":"Aripiprazole in children and adolescents: clinical experience.","volume":"20","author":"Rugino","year":"2005","journal-title":"J Child Neurol"},{"key":"R151-13-20210128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1081\/CLT-53095","article-title":"Atypical experience: a case series of pediatric aripiprazole exposures.","volume":"43","author":"Lofton","year":"2005","journal-title":"Clin Toxicol"},{"key":"R153-13-20210128","first-page":"1550","article-title":"Effect of clozapine on human serum prolactin levels.","volume":"136","author":"Meltzer","year":"1970","journal-title":"Am J Psychiatry"},{"key":"R154-13-20210128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0924-977X(99)00040-1","article-title":"Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients.","volume":"9","author":"Markianos","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"R155-13-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/cap.2005.15.311","article-title":"An open-label trial of risperidone in children and adolescents with bipolar disorder.","volume":"15","author":"Biederman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R156-13-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.chi.0000145805.24274.09","article-title":"Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients.","volume":"44","author":"Croonenberghs","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R157-13-20210128","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1176\/appi.ajp.161.4.677","article-title":"Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.","volume":"161","author":"Findling","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R158-13-20210128","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1542\/peds.110.3.e34","article-title":"Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.","volume":"110","author":"Turgay","year":"2002","journal-title":"Pediatrics"},{"key":"R159-13-20210128","first-page":"107","article-title":"Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204, 636).","volume":"32","author":"Hamner","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"R160-13-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","article-title":"UCU 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US SEROQUEL Study Group.","volume":"16","author":"Borison","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"R161-13-20210128","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1592\/phco.21.7.717.34575","article-title":"Ziprasidone, a new atypical antipsychotic drug.","volume":"21","author":"Carnahan","year":"2001","journal-title":"Pharmacotherapy"},{"key":"R162-13-20210128","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00023210-200216090-00005","article-title":"Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.","volume":"16","author":"Gunasekara","year":"2002","journal-title":"CNS Drugs"},{"key":"R163-13-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cap.2004.14.593","article-title":"The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review.","volume":"14","author":"Barzman","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R164-13-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S1092852900019489","article-title":"Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review.","volume":"10","author":"Biederman","year":"2005","journal-title":"CNS Spectr"},{"key":"R165-13-20210128","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/cap.2004.14.505","article-title":"Aripiprazole in the treatment of bipolar disorder in children and adolescents.","volume":"14","author":"Durkin","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R166-13-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1192\/bjp.187.3.235","article-title":"Effectiveness of aripiprazole v haloperidol in acute bipolar mania. Double-blind, randomized, comparative 12-week trial.","volume":"187","author":"Vieta","year":"2005","journal-title":"Br J Psychiatry"},{"key":"R167-13-20210128","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis.","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R168-13-20210128","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1176\/appi.ajp.162.10.1984-a","article-title":"An update of fast-off dopamine D2 atypical antipsychotics.","volume":"162","author":"Seeman","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R169-13-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R170-13-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","article-title":"A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.","volume":"57","author":"Kapur","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R171-13-20210128","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.156.6.876","article-title":"Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.","volume":"156","author":"Seeman","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R172-13-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0924-977X(00)00133-4","article-title":"D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study.","volume":"11","author":"Gefvert","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"R173-13-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action.","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"R174-13-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0166-4328(96)00097-6","article-title":"Serotonergic regulation of rennin and prolactin secretion.","volume":"73","author":"Van de Kar","year":"1996","journal-title":"Behav Brain Res"},{"key":"R175-13-20210128","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.","volume":"26","author":"DeLeon","year":"2004","journal-title":"Clin Ther"},{"key":"R176-13-20210128","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R178-13-20210128","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia.","volume":"161","author":"Marder","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R179-13-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.schbul.a006926","article-title":"The Mount Sinai conference on the pharmacotherapy of schizophrenia.","volume":"28","author":"Marder","year":"2002","journal-title":"Schizophr Bull"},{"key":"R181-13-20210128","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4088\/JCP.v66n0710","article-title":"The Texas Implementation of Medication Algorithms: update to the algorithms for treatment of bipolar I disorder.","volume":"66","author":"Suppes","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R182-13-20210128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R183-13-20210128","first-page":"895","article-title":"Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting.","volume":"76","author":"Ansbacher","year":"1990","journal-title":"Obstet Gynecol"},{"key":"R184-13-20210128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S1461145704005012","article-title":"Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation.","volume":"8","author":"Dossenbach","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R187-13-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"R188-13-20210128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.","volume":"45","author":"Correll","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"suppl 7","key":"R189-13-20210128","first-page":"29","article-title":"Use of antipsychotics in children and adolescents.","volume":"66","author":"Findling","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R190-13-20210128","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2165\/00128072-200103120-00005","article-title":"Tolerability profile of atypical antipsychotics in children and adolescents.","volume":"3","author":"Stigler","year":"2001","journal-title":"Paediatr Drugs"},{"key":"R191-13-20210128","first-page":"737","article-title":"Neuroleptic-associated hyperprolactinemia: can it be treated with bromocriptine?","volume":"37","author":"Smith","year":"1992","journal-title":"J Reprod Med"},{"key":"R192-13-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004714-198912000-00006","article-title":"The behavioral toxicity of bromocriptine in patients with psychiatric illness.","volume":"9","author":"Perovich","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"R193-13-20210128","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0022-5347(05)61077-4","article-title":"Management of hyperprolactinemia in patients receiving antipsychotics.","volume":"173","author":"Miller","year":"2005","journal-title":"J Urol"},{"issue":"suppl 4","key":"R194-13-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1399-5618.2005.00212.x","article-title":"Atypical antipsychotics: newer options for mania and maintenance therapy.","volume":"7","author":"Vieta","year":"2005","journal-title":"Bipolar Disord"},{"key":"R195-13-20210128","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-2406.2003.00063.x","article-title":"Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management.","volume":"5","author":"Chue","year":"2003","journal-title":"Bipolar Disord"},{"key":"R196-13-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00148581-200507050-00002","article-title":"Management options for bipolar disorder in children and adolescents.","volume":"7","author":"Danielyan","year":"2005","journal-title":"Pediatr Drugs"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200712000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T07:19:34Z","timestamp":1684912774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200712000-00013"}},"subtitle":["Recent Developments and Current Perspectives"],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":182,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31815ac4e5","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}